Boston University
Effects of the reduction of forebrain IGF2 levels and choline supplementation in a mouse model of Alzheimer’s disease
Abstract
dc:description.abstractAlzheimer’s Disease (AD) is a common dementia disorder of older adults. Neuropathologically, it is characterized by beta-amyloid (Aβ) plaques, derived from the processing of the amyloid precursor protein (APP), and neurofibrillary tangles composed of hyperphosphorylated tau within the brain. There is no cure for AD, though there are treatments that can improve the symptoms of the disease. In animal models of AD, perinatal supplementation with the essential nutrient, choline, ameliorates cognitive deficits and reduces brain amyloidosis and gliosis. Moreover, perinatal choline supplementation induces the expression of insulin-like growth factor 2 (IGF2) in rodent brain and studies in mice have shown that exogenous IGF2 has cognitive enhancing activity and antiamyloidogenic actions in models of AD. In this study we tested the hypothesis that IGF2 knockdown would exacerbate AD-related phenotypes and attenuate the beneficial effects of perinatal choline supplementation in an AD mouse model. For this purpose, we used the transgenic APP.PS1 mice which express a mutant form of APP and presenilin 1 (PS1) causing familial forms of AD and harboring floxed Igf2 alleles and an estrogen receptor activated Cre recombinase under the control of the neuronal forebrain promoter, CaMK2a. These AD model mice, and their appropriate wild type (WT) litter mates, were raised on the control- (8 mmol/kg) or a choline-supplemented diet (36 mmol/kg) from conception to weaning and subsequently all mice received the control diet. On postnatal days (P) 60-70, the mice were treated with tamoxifen to activate Cre to delete the Igf2 gene. On P100, the mice underwent behavioral testing and subsequent assays of AD-related proteins using immunoblotting. At this age, the mice would be expected to exhibit mild AD-related phenotypes which tend to develop at older ages. Indeed, no behavioral abnormalities were seen in these mice. We found no evidence of IGF2 knockdown in the Cre-expressing mice using immunoblotting. These results will have to be verified by additional assays. However, activation of the Cre caused dramatic reduction of the levels of hippocampal APP, particularly in the females suggesting that the IGF2 downregulation may have occurred. APP.PS1 female mouse hippocampus was characterized by high expression of the microglial marker, Iba1, and Cre activation also induced Iba1 the in the WT animals suggesting that reduction of IGF2 levels had proinflammatory actions. Perinatal choline supplementation attenuated these effects. In contrast, perinatal choline supplementation reduced the levels of the glial acidic glycoprotein (GFAP) in the hippocampus of WT mice and increased its levels in the APP.PS1 mice. There were no effects of Cre activation on GFAP levels. Taken together the data are consistent with the notion that endogenous IGF2 modulates AD-related phenotypes. Additional studies will be needed to determine the quantitative relationships between IGF2 expression and these phenotypes.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Anderson, Monae
- Advisors dc:contributor.advisor
-
- Mellott, Tiffany
- Blusztajn, Jan Krzysztof
- ORCID dc:identifier.orcid
Subjects
dc:subject × 7Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Licence dc:rights.uri
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/51290